Details

Optimization of 6-(trifluoromethyl)pyrimidine derivatives as TLR8 antagonists
ID Strašek Benedik, Nika (Author), ID Talagayev, Valerij (Author), ID Matziol, Troy (Author), ID Dolšak, Ana (Author), ID Sosič, Izidor (Author), ID Weindl, Günther (Author), ID Wolber, Gerhard (Author), ID Sova, Matej (Author)

.pdfPDF - Presentation file, Download (1,49 MB)
MD5: 72F50DE7A5EA00C48A634E3E0739ED9B
URLURL - Source URL, Visit https://acta.pharmaceutica.farmaceut.org/wp-content/uploads/2025/06/15925.pdf This link opens in a new window

Abstract
Toll-like receptors (TLRs) are essential for the innate immune system as they recognize pathogen-associated molecular patterns and trigger immune responses. Overactivation of TLR8 by endogenous nucleic acids is associated with the development of autoimmune diseases and promotes inflammatory responses. This study presents the design, synthesis, and evaluation of a series of TLR8 antagonists based on the optimization of previously reported 6-(trifluoromethyl)pyrimidin-2-amines, with targeted modifications to further explore structure-activity relationships (SAR) and increase potency. A two-step synthesis involving nucleophilic aromatic substitution and Suzuki coupling was used to prepare two series of new compounds. The biological evaluation revealed that compounds 14 and 26 exhibited promising TLR8 antagonistic activity with IC$_{50}$ values of 6.5 and 8.7 μmol L$^{-1}$, respectively. Compound 14 showed reduced cell viability at higher concentrations, while compound 26 showed no cytotoxic effects, making it a promising candidate for further investigation.

Language:English
Keywords:Toll-like receptors, TLR8 antagonists, autoimmune disorders, immunomodulation, pyrimidines
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:Str. 159-183
Numbering:Vol. 75, iss. 2
PID:20.500.12556/RUL-169976 This link opens in a new window
UDC:616-097
ISSN on article:1846-9558
DOI:10.2478/acph-2025-0011 This link opens in a new window
COBISS.SI-ID:240657155 This link opens in a new window
Publication date in RUL:30.06.2025
Views:665
Downloads:259
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Acta pharmaceutica
Shortened title:Acta pharm.
Publisher:Croatian Pharmaceutical Society
ISSN:1846-9558
COBISS.SI-ID:3817585 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:imunomodulacija, Toll-u podobni receptorji, antagonisti TLR8, avtoimunske motnje

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-4417
Name:Razvoj novih nizkomolekularnih modulatorjev Tollu podobnih receptorjev 7 in 8 za imunoterapijo raka

Funder:Other - Other funder or multiple funders
Project number:BIDE/23-24-011
Name:Bilateral project

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back